N-[2-[4-(Aminosulfonyl)-phenyl]-ethyl]-5-methyl-2-pyrazinecarboxamide
CAS: 33288-71-0
Ref. 3D-FA150607
1g | 991,00 € | ||
50mg | 136,00 € | ||
100mg | 190,00 € | ||
250mg | 396,00 € | ||
500mg | 687,00 € |
Información del producto
- 2-pyrazinecarboxamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-5-methyl-
- 4-[2-(5-Methyl-2-pyrazine carboxamido)ethyl]benzene sulfonamide
- 4-[2-(5-Methylpyrazine-2-carboxamido)ethyl]benzenesulfonamide
- 4-[2-(5-Methylpyrazinyl-2-carboxamido)ethyl]benzenesulfonamide
- 5-Methyl-N-[2-(4-sulfamoylphenyl)ethyl]pyrazine-2-carboxamide
- N-[2-[4-(Aminosulfonyl)phenyl]ethyl]-5-methyl-2-pyrazinecarboxamide
- Pyrazinecarboxamide, 5-methyl-N-(p-sulfamoylphenethyl)-
- Pyrazinecarboxamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-5-methyl-
Fluoxetine is a potent inhibitor of the enzyme cytochrome P450 (CYP) 2C19. The inhibition of CYP2C19 by fluoxetine may lead to an increase in the plasma concentration of other drugs that are metabolized by this enzyme, such as glipizide and hydroxycyclohexyl. Fluoxetine inhibits human uric acid secretion and increases plasma concentrations of uric acid. This drug also inhibits human erythrocyte dihydropyrimidine dehydrogenase, leading to increased blood levels of pyrimidines, especially cytotoxic ones like 6-fluoro-3-indoxyl-beta-D-galactopyranoside. Fluoxetine has been shown to have a protective effect against acetaminophen toxicity in rats because it enhances the conversion of acetaminophen to its less toxic metabolite N-acetylcysteine.
Propiedades químicas
Consulta técnica sobre: 3D-FA150607 N-[2-[4-(Aminosulfonyl)-phenyl]-ethyl]-5-methyl-2-pyrazinecarboxamide
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.